The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-29 and is reviewed periodically as new material appears.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
=== University of Nebraska Medical Center === Markin was awarded the Ida Ittner Postdoctoral Fellowship studying lead toxicity in children from 1980 to 1982, working in the laboratory of Dr. Carol R. Angle. In 2005, Markin was named the David T. Purtilo Professor of Pathology and Microbiology. Markin helped develop Children's Specialty Physicians, the pediatric practice plan for the UNMC College of Medicine at Children's Hospital & Medical Center. Markin also holds appointments in the Departments of Surgery and Psychiatry. Markin was inducted into the National Academy of Inventors Fellows Class of 2015. He has also received the Lifetime Achievement Award from UNeMed Corporation, UNMC's technology transfer office, for his innovations that have transformed the clinical laboratory. Markin leads the telehealth initiative of UNMC and Nebraska Medicine. Since 2011, he has served as associate vice chancellor for business development and as chief technology officer. In October 2005, the U.S. Defense Department provided a grant to Markin and his team to design a new method for microbiology automation. Known as the Microbiology Automation Research Project, or "MARP," the project is designed to develop a broad platform that can be used in the clinical laboratory, including applications for bacteriology, mycology and virology. Additionally, the project has potential uses for other applications, including bioterrorism testing, and holds significant promise for the civilian sector. Markin holds several patents, and has written numerous industry articles on laboratory automation.
=== Metallocenophanes === Metallocenophanes feature linking of the cyclopentadienyl or polyarenyl rings by the introduction of one or more heteroannular bridges. Some of these compounds undergo thermal ring-opening polymerizations to give soluble high molecular weight polymers with transition metals in the polymer backbone. Ansa-metallocenes are derivatives of metallocenes with an intramolecular bridge between the two cyclopentadienyl rings.
== Further reading == Boyer PD, Lardy H, Myrback K, eds. (1963). The Enzymes. Vol. 7 (2nd ed.). New York: Academic Press. pp. 243–273. Warburg O, Christian W (1939). "Isolierung und Krystallisation des Proteins des oxydierenden Garungsferments". Biochem. Z. 303: 40–68.
== Diving spread == The diving spread is a commercial diving term for the topside dive site infrastructure supporting the diving operations for a diving project. The diving contractor provides the diving and support equipment and sets it up on site, usually at a place provided for the purpose by the client, or on a diving support vessel. Two types of diving spread are in common use: Air spreads for surface oriented diving operations, where the divers are deployed from normal atmospheric pressure, and decompressed back to atmospheric pressure at the end of the dive, either in-water, or in a chamber for surface decompression, using compressed air as the primary breathing gas, and saturation spreads, where divers are deployed under pressure from the saturation accommodation via a closed diving bell to the underwater worksite, and returned under pressure in the bell to the saturation accommodation system, usually breathing a helium based gas mixture. At the end of their contract the divers are decompressed to surface pressure. The process of selecting, transporting, setting up and testing the equipment is the mobilisation stage of the project, and the demobilisation involves dismantling, transportation and return to storage of the spread components. Surface oriented mixed gas diving spreads may also be used, but are less common, and are likely to be associated with projects which are too deep for air but require only a short working time at depth.
Sources: en.wikipedia.org
== External links == Deutsch M (17 June 2016). "Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People" (2nd ed.). University of California, San Francisco: Center of Excellence for Transgender Health. p. 28. Bourns A (2015). "Guidelines and Protocols for Comprehensive Primary Care for Trans Clients" (PDF). Sherbourne Health Centre. Retrieved 15 August 2018. Transgender HRT Research Repository Archived 2022-09-14 at the Wayback Machine
== Critical response == The Guardian editor Alex Macpherson praised the production: "Thr33 Ringz' humour is still superbly crass and mostly enjoyable, especially when allied with the skittering beats and post-funk bounce of Freeze." Jesal 'Jay Soul' Padania of RapReviews.com called this song nice enough. Eric Henderson wrote a positive review: "Freeze" might be another freeze-dried Chris Brown upper, but it boasts the cleanest production this side of Ne-Yo."
At higher temperatures, the fluid starts to behave more like an ideal gas, with a more linear density/pressure relationship, as can be seen in Figure 2. For carbon dioxide at 400 K, the density increases almost linearly with pressure. Many pressurized gases are actually supercritical fluids. For example, nitrogen has a critical point of 126.2 K (−147.0 °C; −232.5 °F) and 3.4 MPa (34 bar). Therefore, nitrogen (or compressed air) in a gas cylinder above this pressure is actually a supercritical fluid. These are more often known as permanent gases. At room temperature, they are well above their critical temperature, and therefore behave as a nearly ideal gas, similar to CO2 at 400 K above. However, they cannot be liquified by mechanical pressure unless cooled below their critical temperature, requiring gravitational pressure such as within gas giants to produce a liquid or solid at high temperatures. Above the critical temperature, elevated pressures can increase the density enough that the SCF exhibits liquid-like density and behaviour. At very high pressures, an SCF can be compressed into a solid because the melting curve extends to the right of the critical point in the P/T phase diagram. While the pressure required to compress supercritical CO2 into a solid can be, depending on the temperature, as low as 570 MPa, that required to solidify supercritical water is 14,000 MPa. The Fisher–Widom line, the Widom line, or the Frenkel line are thermodynamic concepts that allow to distinguish liquid-like and gas-like states within the supercritical fluid.
=== Current and resistance === The resistance of the filament is temperature dependent. The cold resistance of tungsten-filament lamps is about 1⁄15 the resistance when operating. For example, a 100-watt, 120-volt lamp has a resistance of 144 ohms when lit, but the cold resistance is much lower (about 9.5 ohms). Since incandescent lamps are resistive loads, simple phase-control TRIAC dimmers can be used to control brightness. Electrical contacts may carry a "T" rating symbol indicating that they are designed to control circuits with the high inrush current characteristic of tungsten lamps. For a 100-watt, 120-volt general-service lamp, the current stabilizes in about 0.10 seconds, and the lamp reaches 90% of its full brightness after about 0.13 seconds.
=== Increased synthesis of ATF4 === In homeostasis, eIF2 combines with guanosine triphosphate (GTP) to activate the mRNA which will start transcription and simultaneously lead to the hydrolysis of GTP so that the process can start again. However during an essential amino acid shortage, P-eIF2α is phosphorylated and binds tightly to eIF2B preventing GDP from turning back to GTP leading to fewer mRNAs being activated and fewer proteins being synthesized. This response causes translation to be increased for some mRNAs, including ATF4, which regulates the transcription of other genes.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.